Gilead Sciences (GILD) Income from Continuing Operations (2016 - 2026)
Gilead Sciences filings provide 17 years of Income from Continuing Operations readings, the most recent being 2528000000.0 for Q4 2025.
- On a quarterly basis, Income from Continuing Operations rose 41.86% to 2528000000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 8856000000.0, a 1748.85% increase, with the full-year FY2025 number at 8510000000.0, up 1676.62% from a year prior.
- Income from Continuing Operations hit 2528000000.0 in Q4 2025 for Gilead Sciences, down from 3052000000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 3052000000.0 in Q3 2025 to a low of 4171000000.0 in Q1 2024.
- Median Income from Continuing Operations over the past 5 years was 1566000000.0 (2021), compared with a mean of 1285650000.0.
- Biggest five-year swings in Income from Continuing Operations: soared 8100.0% in 2023 and later tumbled 523.88% in 2024.
- Gilead Sciences' Income from Continuing Operations stood at 376000000.0 in 2021, then surged by 334.31% to 1633000000.0 in 2022, then fell by 13.29% to 1416000000.0 in 2023, then grew by 25.85% to 1782000000.0 in 2024, then surged by 41.86% to 2528000000.0 in 2025.
- The last three reported values for Income from Continuing Operations were 2528000000.0 (Q4 2025), 3052000000.0 (Q3 2025), and 1961000000.0 (Q2 2025) per Business Quant data.